Navigation Links
PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Date:12/4/2009

C1 AI067223-01) from the National Institutes of Health.

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance, (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® -- a fully human monoclonal antibody for the prevention
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/20/2014)... Northstar Global Business Services, Inc., Symbol ... hard work from many talented specialists, the company ... package design.  The new formulation for Snorenz original ... product due to overwhelming evidence of increased efficacy ... will also include these vitamins, as well as ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down methamphetamine offenders and make arrests. Data ... Missouri blocked the sale of ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... England Journal of Medicine employs Quest Diagnostics, blood-based leukemia ... blood specimens may detect abnormal white blood cells in ... (CLL) develops, according to research published in the current ... of Medicine . The finding may lead to a ...
... ROCKVILLE, Md., Feb. 19 Hospital associations in ... a program to test methods of reducing central-line ... units (ICUs), according to HHS, Agency for Healthcare ... Massachusetts, Nebraska, North Carolina, Ohio, Pennsylvania, Texas, and ...
Cached Medicine Technology:Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 410-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 210-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 3
(Date:8/21/2014)... born at a low birth weight puts black women at ... The findings may partly explain high diabetes rates among ... low birth weight, the researchers added. Their study of ... low birth weight were 13 percent more likely to develop ... The risk of diabetes was 40 percent higher in those ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, ... antidepressants appears to best help people with severe but ... of five people suffering from severe depression for less ... cognitive therapy plus antidepressant medication, researchers found. On ... than drugs alone in helping people with mild depression ...
(Date:8/21/2014)... August 21, 2014 Transvaginal mesh ... Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. ... 14th, the Court has established new stipulated evidence ... handling, division, storage and preservation. (In re C.R. ...
(Date:8/21/2014)... August 21, 2014 Seattle, WA ... at Eastlake Chiropractic and Massage Center have ... growing team. Rina Lang, LMP and Mike Larios, ... range of massage techniques, and have developed their expertise ... This is particularly important in a clinical environment where ...
(Date:8/21/2014)... do not routinely screen women for intimate partner ... public health researchers. Rural women who are exposed ... seek help., "Rural health care providers are uniquely ... a primary care physician and assistant professor of ... of Medicine. "However, in rural settings, it might ...
Breaking Medicine News(10 mins):Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2
... ... preparedness and response efforts for the H1N1 pandemic have a new resource at their ... Minneapolis ... and response efforts for the H1N1 pandemic have a new resource at their disposal. ...
... Time for Senate to Act , WASHINGTON, Nov. 9 ... Win: , After generations of struggle and decades of delay, the ... to pass historic reform legislation to assure every American, regardless of ... House,s action this November is why working men and women turned ...
... The House version of health care reform - the Affordable ... of 220-215 on Saturday, November 7, 2009 - mandates several significant ... the tax provisions likely to appear in any Senate version, requiring ... Special Tax Briefing on the tax provisions of ...
... Churchill Centre today announced that it plans to bestow its ... commitment to promoting democracy through progressive free market practices and ... will receive his award at a ceremony and dinner on ... , "This is a testament to how Bill Marriott ...
... drugs that inhibit estrogen, , MONDAY, Nov. 9 (HealthDay ... and osteoporosis eliminated cervical cancer in mice, according to ... growths in the cervix and vagina, and prevented the ... The breast cancer drug fulvestrant and the breast cancer/osteoporosis ...
... ... Understanding the Effects of Genes , ... (Vocus) November 9, 2009 -- Understanding patients’ ancestries can be extraordinarily ... that scanned the genomes of 4,000 people throughout Europe and found clear regional differences, ...
Cached Medicine News:Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 2Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 3Health News:Statement of Anna Burger, Chair, Change to Win, on U.S. House Vote for Health Care Reform 2Health News:CCH Briefing Details Tax Provisions of House Health Care Bill 2Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:News from the November/December Issue of Molecular Medicine 2
... Universal Biomedical Amplifier (UBA-4204) from ... DC signal amplification and complete ... seen amplifier problems of DC ... These features make the amplifier ...
... 3 uses the exact enhanced corneal thickness ... pachymeters used exclusively by the OHTS investigators. ... the software. The new backlit LCD character ... standard deviation and IOP correction calculation and ...
Orbital Retractor, schepens Retractors, overall length:154mm....
Stainless Steel. Box of 1, non sterile...
Medicine Products: